Foresite Capital β 2015 Investments
7 investments dated 2015 Β· listed companies and verified rows first Β· show all
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)Tillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in
BoardCarl Gordon(Director)Terry McGuire(Director)in
Co-investorsMission Bay CapitalMission BiocapitalMRL Ventures FundSV Health InvestorsPolaris Partners
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Executive Officer, Director)Jennifer Doudna(Co-founder)Jose Rivera(Executive Officer)John Leonard(President and Chief Executive Officer)James Basta(Executive Vice President, General Counsel and Corporate Secretary)Edward Dulac(Executive Vice President, Chief Financial Officer)
Co-investorsage1Atlas VentureAvoro Capital AdvisorsEcoR1 Capital
HealthtechSan Mateo, US
Victor Colunga(Executive Officer)Stephen G. Dilly, Jr.(Executive Officer, Director)
BoardJoonkyoo (Anthony) Yun(Director)Stacey D. Seltzer(Director)Patrick Enright(Director)
Board seatJames TananbaumΒ· per SEC Form D Β· $80M raise Β· filed Mar 2015
Co-investorsQiming Healthcare
Corvus is a clinical-stage biopharmaceutical company developing therapies for immune diseases and cancer.
BiotechHealthtechBurlingame, US
Richard A. Miller(Executive Officer, Director)Leiv Lea(Executive Officer)Terry G. Gould(Director)
BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Director)
Co-investorsAvoro Capital AdvisorsOrbiMed
Gilead Sciences is a biopharmaceutical company that develops medicines across virology, oncology, and inflammation, with more than 25 medicines offered globally and a clinical pipeline spanning these three therapeutic areas.
BiotechHealthtechNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)
BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)
Co-investorsAvoro Capital AdvisorsBay City CapitalVantagePoint Capital Partners
DNAnexus operates a cloud platform for managing, analyzing, and collaborating on multiomic and clinical data, supporting bioinformatics workflows, AI/ML analytics, and cohort analysis.
AI & Machine LearningBiotechCloud ComputingData & InfrastructureMountain View, US
Andreas Sundquist(Executive Officer, Director)Richard Daly(Executive Officer, Director)George Asimenos, PhD(Chief Product Officer)in
BoardMICHAEL GOLDBERG(Director)GEOFF DUYK(Director)KRISHNA YESHWANT(Director)in
Co-investorsClaremont Creek VenturesGV (Google Ventures)K9 VenturesUncork CapitalWireframe Ventures
BiotechSouth San Francisco, US
Tassos Anastasios Gianakakos(Executive Officer, Director)
BoardKevin Starr(Director)inCharles Homcy(Director)Mark Perry(Director)Katherine Bowdish(Director)
Co-investorsKhosla VenturesThird Rock Ventures
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.